Life Science-podden: The perfect moment for an IPO

When is the right time to go for an IPO? What strategy is recommended in today´s rather uncertain business climate when it comes to taking your life science company public?

Swedish-Danish meeting at Medicon Village: “One of the most important life science congresses”

For the eleventh year, The Future of Swedish and Danish Life Science was held on Wednesday, and the event continues to function as a connecting link between the life science sectors of both countries. This year’s event attracted nearly 450 visitors.

Karriärcoachen: Så är du en bra chef – och det här ska du undvika

Hösten har dragit igång och därmed har många bytt jobb – kanske har du landat ett chefsjobb och funderar på hur du nu ska agera. Enligt karriärcoachen Tina Persson är det viktigaste att förstå sin position i företaget för att kunna vara en bra chef.

Vårdrepresentanter hoppas på större statligt ansvar nästa mandatperiod

Valnatten blev en rysare och idag, måndag, är utgången fortfarande oviss med en fördel för högerblocket med en mandat.

Johan Dahlin går till BMS

Från kommunikationschef på Janssen Sverige till Associate Director Corporate Affairs på Bristol Myers Squibb – den 3 oktober stiger Johan Dahlin in på BMS:s kontor i Solna.

Konferens om läkemedelsformuleringar samlar branschen i Köpenhamn

Idag pågår den tionde upplagan av New Updates in Drug Formulation & Bioavailability 2022 i Köpenhamn.

Anders Blanck about his 17 years at Lif: “The industry is enjoying greater public trust now"

The announcement came as a surprise to those around him, but according to the protagonist himself, the timing was excellent. Anders Blanck is now leaving Lif – a decision that has been growing for some time. “I have been pretty much married to my mission. However, I will turn 56 this autumn, and if I’m going to do something else in my professional life, now is the time,” he says.

Genes from Neanderthals can affect the correct drug dosage

A fifth of all Europeans carry gene variants inherited from Neanderthals, which cause certain drugs to break down more slowly. This may have implications for the drug doses they should take.

Anna Törner: Kalashnikovs in a new guise

Thanks to resisting European regulatory authorities, Europe has been spared the opioid epidemic. In the 1960s, the situation was the opposite as the American pharmaceutical authority, the Food and Drug Administration (FDA), refused to approve thalidomide (Neurosedyn), writes Anna Törner in a column.

Isofol avbryter cancerstudie efter ytterligare nedslående data

Det är inte motiverat att driva Agent-studien kring metastaserande kolorektalcancer vidare. Den bedömningen gör Isofol Medical efter granskning av nya studiedata.

Xintelas styrelse rekommenderar: Nobba uppköpsbudet

Biomedicinbolaget Xintelas styrelse rekommenderar aktieägarna att säga nej till ett uppköpserbjudande från Flerie Invest. "Detta baseras främst på den framtida potentialen och att Flerie Invests ambition inte varit att förvärva samtliga aktier", skriver styrelsen i ett pressmeddelande.

Lucy Robertshaw: Did you know Stockholm wants to be in top 5 in the world for Life Sciences?

Karolinska Institutet Solna Campus has certainly become the next “Kendall Square”, writes Lucy Robertshaw in a column.

Gen från neandertalare kan påverka rätt läkemedelsdosering

En femtedel av alla européer bär på genvarianter nedärvda från neandertalarna som gör att vissa läkemedel bryts ned långsammare. Det kan ha betydelse för vilka doser av läkemedlen de bör ta.

Sweden is heavily criticised for not ordering Covid vaccine

Valneva and the EU Commission have entered into an agreement for 1.25 million doses of the company’s Covid vaccine, but Sweden has not placed an order.

Newly discovered gene variant linked to protection against abdominal obesity

American researchers believe they have identified a rare gene mutation that protects against abdominal obesity and metabolic syndrome. The ambition is that the discovery will lead to new treatments that can help reduce the risk of type 2 diabetes

Amorphous materials take centre stage when Orexo develops new formulations

Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s

Pilotstudie: Implantat från grishud alternativ till donerade hornhinnor

Linköpingsforskare har utvecklat ett implantat byggt på protein från grishud som efterliknar den mänskliga hornhinnan. Positiva resultat presenteras nu från en pilotstudie.

BioVentureHub CEO: “Companies with a high degree of interaction achieve greater success”

For the first time since its inception, AstraZeneca’s BioVentureHub can now recruit new companies, as some of its tenants have grown significantly and are leaving the hub. This is the message from the biohub’s CEO Magnus Björsne in an interview, in which

Presschef lämnar Folkhälsomyndigheten

Tablet treatment for hair loss approved in the USA

The US Drug Administration has given a thumbs up for the first tablet treatment for spotty hair loss.

Collaboration for a simpler production of gene therapies launched

A collaboration between universities and companies aims at providing better production methods for the development of gene therapies. The initiative is led by Johan Rockberg, Professor at KTH.

Study: Our behaviour may have been guided by wishful thinking during the pandemic

A new study suggests that we systematically underestimate health risks if and when it suits us. This was especially true during the pandemic, as our risk assessments may have been guided by wishful thinking rather than a rational perception of the risks.

Björn Arvidsson: “We need robust and recognized ecosystems for continued competitiveness”

“We have idea carriers and excellent innovation opportunities, and now we must invest in creating ecosystems that provide them with even better growth opportunities,” Björn Arvidsson writes in a column.

Göran Stiernstedt: “We are the world’s worst at continuity”

Failed investments in primary care, an unreasonable system with online doctors and a public failure at coordinating the healthcare IT system. Göran Stiernstedt does not mind his language when describing the shortcomings of today’s healthcare system. “It makes me extremely frustrated,” he says.